The NSAIDs Ibuprofen and Celecoxib and the TNF-α Blocker Etanercept Prevented Cyclosporine A-Induced Depression-Like Behavior in Mice

Yıl 2021, , 133 - 142, 01.09.2021

Azadeh Mesripour , Farnaz Gasemi

https://doi.org/10.52794/hujpharm.962540

Öz

Cyclosporine A (CYA), is used to prevent graft rejection, but it may cause depres- sion in individuals. Anti-inflammatory drugs are associated with antidepressant effects, the aim was evaluating the effect of nonsteroidal anti-inflammatory drugs (NSAID) (ibuprofen, celecoxib), and tumor necrosis factor-α blocker (etanercept) pretreatment on depressive behavior induced by CYA (20 mg/kg) in male mice (25±2 g). The pretreatment with ibuprofen (50 mg/kg), or celecoxib (25 mg/kg) were applied intraperitoneal for 3 days. Etanercept (1 mg/kg) subcutaneously was injected on days 1 and 3. After the locomotor test, immobility during the forced swimming test (FST), and sucrose preference (SP) were evaluated. Pretreatment with each of the drugs ibuprofen, celecoxib, and etanercept reversed the increased immobility time during FST induced by CYA after the first dose (149±7.07 s vs. control 100±10.4 s, p<0.01) and the last dose (179±6.4 s vs. control group 101±16 s, p<0.01). The SP increased following pretreatment with the selected drugs. While, the treatments did not cause significant changes in the locomotor test. The NSAIDs, and etanercept reversed CYA despair behavior during FST and anhedonia in SP test. Therefore the co-administrating of these drugs with CYA may be useful in preventing CYA psychological side effects that warrants precise evaluations.

Anahtar Kelimeler

nonsteroidal anti-inflammatory drugs (NSAID), tumor necrosis factor-α, depression, cyclosporine

Destekleyen Kurum

Isfahan University of Medical Sciences

Proje Numarası

399190, 4/20/2020

Teşekkür

This work was supported by the School of Pharmacy and Pharmaceutical Sciences Research Council, Isfahan University of Medical Sciences

Kaynakça

• 1. Einollahi, B., Teimoori, M. A systematic review about an advance in cyclosporine monitoring in kidney transplant recipients. Nephrourol. Mon, 9, (2017).
• 2. Kipanyula, M. J., Kimaro, W. H., Etet, P. F. S. The Emerging Roles of the Calcineurin-Nuclear Factor of Activated T-Lymphocytes Pathway in Nervous System Functions and Diseases. J. Aging Res, 2016, 5081021 (2016).
• 3. Liddicoat, A. M., Lavelle, E. C. Modulation of innate immunity by cyclosporine A. Biochemical. Pharmacology,163, 472–480 (2019).
• 4. Mesripour, A., Golbidi, M., Hajhashemi, V. Dextromethorphan improved cyclosporine-induced depression in mice model of despair. Res. Pharm. Sc,. 15, 447 (2020).
• 5. Mineur, Y. S., Taylor, S. R., Picciotto, M. R. Calcineurin downregulation in the amygdala is sufficient to induce anxiety-like and depression-like behaviors in C57BL/6J male mice. Biol. Psychiatry, 75, 991–998 (2014).
• 6. Margaretten, M., Julian, L., Katz, P., Yelin, E. Depression in patients with rheumatoid arthritis: Description, causes and mechanisms. Int. J. Clin. Rheumto,. 6, 617–623 (2011).
• 7. Davis, A., Gilhooley, M., Agius, M. Using non-steroidal anti-inflammatory drugs in the treatment of depression. Psychiatria. Danubina, 22, S49-52 (2010).
• 8. Köhler, O. et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry,71, 1381–1391 (2014).
• 9. Leonard, B. E. Impact of inflammation on neurotransmitter changes in major depression: An insight into the action of antidepressants. Prog. Neuro-Psychopharmacology Biol. Psychiatry, 48, 261–267 (2014).
• 10. Holbrook, J., Lara-Reyna, S., Jarosz-Griffiths, H., McDermott, M. Tumour necrosis factor signalling in health and disease. F1000Res, 8 (2019).
• 11. Wajant, H., Siegmund, D. TNFR1 and TNFR2 in the control of the life and death balance of macrophages. Front. Cell Dev. Biol, 7, 91 (2019).
• 12. Rawla, P. Cardiac and vascular complications in rheumatoid arthritis. Reumatologia, 57, 27–36 (2019).
• 13. Montfort, A., Colacios, C., Levade, T., Andrieu-Abadie, N., Meyer, N., Ségui, B. The TNF paradox in cancer progression and immunotherapy. Fron. Immunol, 10, 1818 (2019).
• 14. Himmerich, H., Patsalos, O., Lichtblau, N., Ibrahim, M. A. A., Dalton, B. Cytokine research in depression: Principles, challenges, and open questions. Front. Psychiatry, 10, 30 (2019).
• 15. Tyring, S. et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial. Lancet, 367, 29–35 (2006).
• 16. El-Yazbi, A. F., Eid, A. H., El-Mas, M. M. Cardiovascular and renal interactions between cyclosporine and NSAIDs: Underlying mechanisms and clinical relevance. Pharmacol. Res, 129, 251–261 (2018).
• 17. Safaeian, L., Hajhashemi, V., Ajoodanian, M. The effect of celecoxib on blood pressure and plasma oxidant/antioxidant status in co-administration with glucocorticoid in rat. Biomed. Pharmacother. 108, 1804–1808 (2018).
• 18. Mesripour, A., Shahnooshi, S., Hajhashemi, V. Celecoxib, ibuprofen, and indomethacin alleviate depression-like behavior induced by interferon-alfa in mice. J. Complement. Integr. Med. 17, (2020).
• 19. Brymer, K. J., Fenton, E. Y., Kalynchuk, L. E., Caruncho, H. J. Peripheral etanercept administration normalizes behavior, hippocampal neurogenesis, and hippocampal reelin and GABAA receptor expression in a preclinical model of depression. Front. Pharmacol, 9, (2018).
• 20. Moreau, M. et al. Inoculation of Bacillus Calmette-Guerin to mice induces an acute episode of sickness behavior followed by chronic depressive-like behavior. Brain. Behav. Immun, 22, 1087–1095 (2008).
• 21. Planchez, B., Surget, A., Belzung, C. Animal models of major depression: drawbacks and challenges. J. Neural. Transm, 126, 1383–1408 (2019).
• 22. Chen, C. C., Hsu, L. W., Huang, L. T., Huang, T. L. Chronic administration of cyclosporine a changes expression of BDNF and TrkB in rat hippocampus and midbrain. Neurochem. Res, 35, 1098–1104 (2010).
• 23. Yu, J. J. et al. Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway. Psychopharmacology (Berl), 225, 361–372 (2013).
• 24. Abelaira, H. M., Réus, G. Z., Neotti, M. V., Quevedo, J. The role of mTOR in depression and antidepressant responses. Life Sci, 101 10–14 (2014).
• 25. Sandrini, M., Vitale, G., Pini, L. A. Effect of rofecoxib on nociception and the serotonin system in the rat brain. Inflamm. Res, 51, 154–159 (2002).
• 26. Saleh, L. A. et al. Ibuprofen suppresses depressive like behavior induced by BCG inoculation in mice: Role of nitric oxide and prostaglandin. Pharmacol. Biochem. Behav, 125, 29–39 (2014).
• 27. Krügel, U., Fischer, J., Radicke, S., Sack, U., Himmerich, H. Antidepressant effects of TNF-α blockade in an animal model of depression. J. Psychiatr. Res, 47, 611–616 (2013).
• 28. Kappelmann, N., Lewis, G., Dantzer, R., Jones, P. B., Khandaker, G. M. Antidepressant activity of anti-cytokine treatment: A systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol. Psychiatry, 23, 335–343 (2018).